Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Pfizer Inc (PFE) Price & Performance

GraniteShares 2x Long NVDA Daily ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

GraniteShares 2x Long NVDA Daily ETF vs Pfizer Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $35.28, while Pfizer Inc trades at $27.91 (market cap $158.39B). The key difference: Pfizer Inc pays a 6.19% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and Pfizer Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.

NVDLPFE
Sector
Leveraged / InverseHealth
52-Week High
$43.02$29.02
52-Week Low
$21.76$23.60
Market Cap
$158.39B
Volume
29,869,932
Enterprise Value
$209.89B
Dividend Yield
6.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GraniteShares 2x Long NVDA Daily ETF

NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.18, down 4.01% amid recent volatility. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF recently underwent two 1:3 stock splits in late June 2026, reflecting NVIDIA's continued market leadership in AI semiconductors.

The outlook remains positive given NVIDIA's dominant AI position and earnings beats, though leveraged ETF structure introduces volatility decay risks. Key opportunities include exposure to NVIDIA's growth trajectory, while risks center on market sentiment shifts and the ETF's daily reset mechanism affecting long-term returns.

Pfizer Inc

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GraniteShares 2x Long NVDA Daily ETF

NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.

Read more on NVDL

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE